N/A
N=479
Rapid Blood Culture Identification Panel in Pediatric Patients in Guatemala
Bacteremia · Sepsis
Bottom Line
View on ClinicalTrials.gov: NCT05314816 ↗Enrolled (actual)
479
Serious AEs
0.0%
Results posted
Jun 2024
Primary outcome: Primary: Time to Optimal Antimicrobial Therapy — 31.1; 117.7; 90.0 hours
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Blood culture identification panel (Diagnostic_test)
- Age
- Pediatric, Adult
- Sex
- All
- Sponsor
- University of Colorado, Denver
- Primary completion
- Nov 2022
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Time to Optimal Antimicrobial Therapy |
31.1; 117.7; 90.0 | — |
| SECONDARY Time to Organism Identification |
22.6; 79.8; 76.8 | — |
| SECONDARY Time to Effective Antimicrobial Therapy |
0; 0.2; 3.0 | — |
| SECONDARY All-cause Mortality |
14; 30; 18 | — |
| SECONDARY Length of Hospital Stay |
17; 20; 17 | — |
| SECONDARY Intensive Care Unit Days |
14.3; 14.8; 9.0 | — |
Summary
The purpose of this study is to assess the clinical impact of a rapid multiplex PCR blood culture identification panel on time to optimal antimicrobial therapy when compared to conventional microbiological culture methods in children hospitalized in a low resource setting in Guatemala City.
Eligibility Criteria
Inclusion Criteria
- Age <18 years of age
- First positive blood culture during the hospitalization
Exclusion Criteria
- Non-blood specimens
- Repeat positive blood cultures from the same admission
- Patients who expire prior to positive culture
- Outpatient blood cultures
Data sourced from ClinicalTrials.gov (NCT05314816). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.